Bristol-Myers Squibb, a global biopharma company, has named Jose Baselga as its director, serving as a member of its science and technology committee, it was reported yesterday.
Presently, Dr Baselga is the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and translational research. He brings more than 30 years of clinical and research experience to his new position on the board, and his career history has seen him serve as president for the American Association for Cancer Research.
Giovanni Caforia, chairman and chief executive officer of BMS, said, 'Jose is an internationally-recognised physician scientist in oncology with deep experience in teaching at leading academic institutions, pioneering research for targeted cancer therapies and treating patients. His close engagement with emerging science across biotech and shared focus on patients brings valuable contributions to helping us advance our strategy and pipeline of transformational medicines.'
Galapagos plans to wind down cell therapy business following strategic review
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Revelation Pharma acquires Acacia Apothecary & Wellness
Viatris receives fifth consecutive recognition on Forbes' annual list of World's Best Employers
INOVIO announces inducement grant to new employee
AbbVie's Allergan Aesthetics announces Natrelle supplier agreement with Vizient
Karyopharm Therapeutics awards inducement grants to new employees
POLYTECH Health & Aesthetics announces Poland expansion
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar